Journals / Turkish Journal of Gastroenterology / 2016 / Cilt: 27 - Sayı: 6

Stem cell transplantation for the treatment of liver diseases: A systematic review and meta-analysis

Pages
499–508
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Stem cell infusion through the hepatic artery had better biochemical outcomes than an injection through the portal vein.Conclusion: Our meta-analysis verified that there are clinical and biochemical improvements in patients who suffered from liver diseases after stem cell transplantation, suggesting that stem cell transplantation may be a viable clinical solution for treating such patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/Aims: The therapeutic efficacy of stem cell transplantation in liver diseases has not yet been determined.
📊
Key Findings & Data:Either a fixed-effects model or random-effects model was used to analyze the data.Results: A total of 17 publications involving 21 original studies were included.
💡
Conclusion & Impact:Stem cell infusion through the hepatic artery had better biochemical outcomes than an injection through the portal vein.Conclusion: Our meta-analysis verified that there are clinical and biochemical improvements in patients who suffered from liver diseases after stem cell transplantation, suggesting that stem cell transplantation may be a viable clinical solution for treating such patients.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Background/Aims: The therapeutic efficacy of stem cell transplantation in liver diseases has not yet been determined. The objective of this study was to conduct a meta-analysis to evaluate changes in liver function and clinical outcome following stem cell transplantation in patients with liver disease.Materials and Methods: A literature review of NCBI, Cochrane Library, and MEDLINE was performed. Eligible studies reported liver function indices and prothrombin time (PT) before and after transplantation. The weighted mean difference (WMD) was defined by the distinction before and after stem cell transplantation. Either a fixed-effects model or random-effects model was used to analyze the data.Results: A total of 17 publications involving 21 original studies were included. We found that the levels of serum albumin significantly increased at 4, 8, 12, 24, and 48 weeks after stem cell transplantation compared with that at baseline. Serum alanine aminotransferase levels notably decreased at 1, 3, 4, 12, 24, and 48 weeks after stem cell transplantation. Aspartate aminotransferase levels significantly decreased at 4, 8, 12, and 48 weeks after transplantation. Total bilirubin levels significantly decreased at 4, 12, 24, and 48 weeks after transplantation. PT decreased at 4, 12, 24, and 48 weeks after transplantation. The MELD score significantly decreased at 24 weeks after transplantation. Stem cell infusion through the hepatic artery had better biochemical outcomes than an injection through the portal vein.Conclusion: Our meta-analysis verified that there are clinical and biochemical improvements in patients who suffered from liver diseases after stem cell transplantation, suggesting that stem cell transplantation may be a viable clinical solution for treating such patients.

🔖

Cite This Article

LİU, Z., Lİ, J., Lİ, P., BAİ, M., GUO, Y., HAN, M., ZHANG, F., AHMED, R., JİN, S. (2016). Stem cell transplantation for the treatment of liver diseases: A systematic review and meta-analysis. Turkish Journal of Gastroenterology, Cilt: 27 - Sayı: 6, 499–508. https://ajindex.com/articles/409428

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Tho- raval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013; 58: 593-608.
  2. Holzman MD, Rozga J, Neuzil DF, Griffin D, Moscioni AD, Deme- triou AA. Selective intraportal hepatocyte transplantation in an- albuminemic and Gunn rats. Transplantation 1993; 55: 1213-9. [CrossRef] Dalgetty DM, Medine CN, Iredale JP, Hay DC. Progress and future challenges in stem cell-derived liver technologies. Am J Physiol Gastrointest Liver Physiol 2009; 297: G241-8. [CrossRef] Beavers KL, Cassara JE, Shrestha R. Practice patterns for long-term follow-up of adult-to-adult right lobectomy donors at US trans- plantation centers. Liver Transpl 2003; 9: 645-8. [CrossRef] Ahmed A, Keeffe EB. Current indications and contraindications for liver transplantation. Clin Liver Dis 2007; 11: 227-47. [CrossRef] Smrzova J, Lata J, Simanek V, Ulrichova J. [The bioartificial liver--an alternative in the treatment of acute liver failure]. Vnitr Lek 2000; 46: 218-24. Catapano G. Mass transfer limitations to the performance of membrane bioartificial liver support devices. Int J Artif Organs 1996; 19: 18-35.
  3. Simons BD, Clevers H. Strategies for homeostatic stem cell self- renewal in adult tissues. Cell 2011; 145: 851-62. [CrossRef] Wesson RN, Cameron AM. Stem cells in acute liver failure. Adv Surg 2011; 45: 117-30. [CrossRef] Lagasse E, Connors H, Al-Dhalimy M, et al. Purified hematopoi- etic stem cells can differentiate into hepatocytes in vivo. Nat Med 2000; 6: 1229-34. [CrossRef] Huang XL, Luo L, Luo LY, et al. Clinical outcome of autologous he- matopoietic stem cell infusion via hepatic artery or portal vein in pa- tients with end-stage liver diseases. Chin Med Sci J 2014; 29: 15-22. [CrossRef] Alison MR, Islam S, Lim S. Stem cells in liver regeneration, fibrosis and cancer: the good, the bad and the ugly. J Pathol 2009; 217: 282-98. [CrossRef] Li Z, Hu X, Mao J, et al. Optimization of mesenchymal stem cells (MSCs) delivery dose and route in mice with acute liver injury by bioluminescence imaging. Mol Imaging Biol 2015; 17: 185-94. [CrossRef] Lyra AC, Soares MB, da Silva LF, et al. Feasibility and safety of au- tologous bone marrow mononuclear cell transplantation in pa- tients with advanced chronic liver disease. World J Gastroenterol 2007; 13: 1067-73. [CrossRef] Liu L, Yan Y, Zhou J, et al. Curative effect of combined lamivudine, adefovir dipivoxil, and stem cell transplantation on